MDxHealth SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
MDxHealth announces results from its pivotal clinical validation study for ConfirmMDx for Prostate Cancer
MDxHealth SA:Announces results from its pivotal clinical validation study for ConfirmMDx for Prostate Cancer.DOCUMENT (Detection of Occult Cancer Using Methylated Events in Negative Tissue) validation study validates the ConfirmMDx for Prostate Cancer test as most significant predictor of risk for presence of occult cancer above any other risk factor used to guide decision for repeat biopsy.Study further validates that ConfirmMDx test provides actionable information to improve patient risk stratification men and aid urologists to differentiate prostate-cancer-free men from those who may harbor undetected prostate cancer.
Latest Key Developments in Biotechnology
- NPS Pharmaceuticals Inc announces Japanese MHLW granted orphan drug designation for treatment of Short Bowel Syndrome
- Proteon Therapeutics announces the closing of initial public offering
- Rigel Pharmaceuticals Inc announces change in chairman and chief executive officer
- Sunesis announces publication of REVEAL-1 trial results in the british journal of haematology
- Share this
- Digg this